Schering Corporation

Merck Sharp + Dohme Corp.

Satwant K Narula

Robert A Kastelein

Rene De Waal Malefyt

Donna M Rennick

Paul J Zavodny

Sergio A Lira

Birgit Oppmann

Maria T Wiekowski

Jan E De Vries

Chung-Her Jenh

Richard L Reim

Sidney R Smith

Michael J Ryan

Paul J Leibowitz

Charles A Lunn

Paul C Grint

Timothy R Harward

James M Seeger

Lyle L Moldawer

Herinder K Lonial

Purified genes encoding cytokine from a mammal, reagents related thereto including purified proteins, specific antibodies, and nucleic acids encoding this molecule are provided. Methods of using said reagents and diagnostic kits are also provided.

IL-12P40 and IL-B30 polypeptide complex

Mammalian genes; related reagents and methods

Mammalian cytokines; related reagents and methods

A combination of interleukin 10 and methotrexate is used to suppress autoimmune diseases including arthritis and psoriasis. It has been discovered that administration of a combination of interleukin 10 and methotrexate causes suppression of T cell proliferation. Concurrent use of both agents avoids the toxicity associated with higher doses of methotrexate.

Combined use of interleukin 10 and methotrexate for immuno-modulatory therapy

Stably-transformed human cell lines containing a reporter gene operatively linked to an IL-4-responsive element are provided. In some embodiments a human Fc,RII IL-4-responsive element is used. In other embodiments a human germline &egr; transcript promoter is used as the responsive element. Also provided are methods for using such transformed cell lines to screen for agonists and/or antagonists of human interleukin-4.

Materials and methods for screening human interleukin-4 antagonists/agonists

There is disclosed a method of treating ischemia-reperfusion injury comprising administering an effective amount of Interleukin-10 to a patient suffering or expected to suffer from such injury.

Method for treating or preventing ischemia-reperfusion injury

Stably-transformed human cell lines containing a human gamma interferon-responsive human HLA-DR.alpha. promoter operatively linked to a reporter gene are provided. Also provided are methods for using such transformed cell lines to screen for agonists and/or antagonists of human gamma interferon.

Human gamma interferon antagonist/agonist screen

Stably-transformed human cell lines containing a reporter gene operatively linked to an IL-4-responsive element are provided. In some embodiments a human Fc.sub..epsilon. RII IL-4-responsive element is used. In other embodiments a human germline .epsilon. transcript promoter is used as the responsive element. Also provided are methods for using such transformed cell lines to screen for agonists and/or antagonists of human interleukin-4.

Human interleukin-4 antagonist/agonist screens

A method is provided for treating or preventing inflammatory conditions, in particular septic shock and inflammatory conditions caused by auto-immune diseases, such as inflammatory bowel disease, rheumatoid arthritis, multiple sclerosis, uveitis, and psoriasis. The method comprises administering to a mammal a therapeutically effective amount of IL-10 plus at least one steroid such as betamethasone. Also provided are pharmaceutical compositions and kits comprising IL-10 plus at least one steroid, e.g., betamethasone or its derivatives.

Method for treating inflammation

Strains of E. coli are provided which are capable of secreting heterologous recombinant proteins through the outer cell wall and directly into the culture medium. Methods are also provided for making and identifying such strains, and for using them to make heterologous proteins that have high biological activity, without the need for cell disruption.

E. coli secretory strains

Expression systems which utilize bacteriophage T7 RNA mutant polymerases and promoter regions are provided by this invention. These systems are utilized to produce large quantities of useful polypeptides and proteins.

Growing community of inventors

West Caldwell, NJ, United States of America

Satwant K Narula